The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy

BACKGROUND: Although evidence now suggests cGMP is a negative regulator of cardiac hypertrophy, the direct consequences of the soluble guanylyl cyclase (sGC) activator BAY 58-2667 on cardiac remodeling, independent of changes in hemodynamic load, has not been investigated. In the present study, we t...

Descripción completa

Detalles Bibliográficos
Autores principales: Irvine, Jennifer C., Ganthavee, Virat, Love, Jane E., Alexander, Amy E., Horowitz, John D., Stasch, Johannes-Peter, Kemp-Harper, Barbara K., Ritchie, Rebecca H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492396/
https://www.ncbi.nlm.nih.gov/pubmed/23144773
http://dx.doi.org/10.1371/journal.pone.0044481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492396/
https://www.ncbi.nlm.nih.gov/pubmed/23144773
http://dx.doi.org/10.1371/journal.pone.0044481

Ejemplares similares